Granules Pharmaceuticals secures FDA tentative approval and 180-day exclusivity for Generic Dyanavel XR
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
Subscribe To Our Newsletter & Stay Updated